peratsin húðuð tafla 2 mg
orion corporation - perphenazinum inn - húðuð tafla - 2 mg
peratsin húðuð tafla 4 mg
orion corporation - perphenazinum inn - húðuð tafla - 4 mg
peratsin húðuð tafla 8 mg
orion corporation - perphenazinum inn - húðuð tafla - 8 mg
plasmalyte glucos 50 mg/ml innrennslislyf, lausn 50 mg/ml
baxter medical ab* - glucosum; natrii chloridum; kalii chloridum; magnesii chloridum; natrii acetas; natrii gluconas - innrennslislyf, lausn - 50 mg/ml
sufenta stungulyf, lausn 5 míkróg/ml
piramal critical care b.v. - sufentanilum cítrat - stungulyf, lausn - 5 míkróg/ml
tegretol mixtúra, dreifa 20 mg/ml
novartis healthcare a/s - carbamazepinum inn - mixtúra, dreifa - 20 mg/ml
tegretol tafla 200 mg
novartis healthcare a/s - carbamazepinum inn - tafla - 200 mg
tegretol retard forðatafla 200 mg
novartis healthcare a/s - carbamazepinum inn - forðatafla - 200 mg
tegretol retard forðatafla 400 mg
novartis healthcare a/s - carbamazepinum inn - forðatafla - 400 mg
ztalmy
marinus pharmaceuticals emerald limited - ganaxolone - epileptic syndromes; spasms, infantile - Önnur antiepileptics - ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 to 17 years of age. ztalmy may be continued in patients 18 years of age and older.